2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1666

The Use of Patient-Reported Outcome Measures to Assess Clinical Features of Fibromyalgia in SLE
Abstract Number: 198

The Utility of a Coloring Book As an Adjunct Tool to Teach Musculoskeletal Sonoanatomy: A Pragmatic Randomized Control Trial
Abstract Number: 282

The Utility of Positive ANA Referrals at the University of Chicago
Abstract Number: 1764

The Utility of Serum Angiopoietin-1 and Angiopoietin-2 in Patients with Anti-Neutrophil Cytoplasmic Autoantibody-Associated Vasculitis
Abstract Number: 1426

The Utilization of S100 Proteins Testing in Pediatric Rheumatology Patients in a Tertiary Care Institution and Implications for Care
Abstract Number: 1451

The Value of Adding MRI to a Clinical Treat-to-Target Strategy in Rheumatoid Arthritis Patients in Clinical Remission: Clinical and Radiographic Outcomes from the Imagine-RA Randomized Controlled Trial
Abstract Number: 1608

The Value of Carotid Ultrasound in Cardiovascular Risk Stratification in Patients with Psoriatic Disease
Abstract Number: 303

The Value of the Simplified Ramris-5 in Early RA Patients Under Methotrexate Therapy Using High Field MRI
Abstract Number: 1833

The Vδ2 Subset of Γδt-Cells Are Present at Healthy Human Enthesis and Have Transcriptional and Functional Characteristics Consistent with a Capacity for IL- 17A Production in Response to IL-23
Abstract Number: 371

Therapeutic Efficacy and Safety of Iguratimod in Treating Mild IgG4-Related Diseases
Abstract Number: 2279

Therapeutic Value of Canakinumab in Patients with Yao Syndrome
Abstract Number: 324

Three Health It Interventions Increased Documentation of RA Disease Activity Scores in an Academic Rheumatology Clinic: Results from an Interrupted Time Series Study
Abstract Number: 555

Three Year Outcomes of Patients with Elderly-Onset Rheumatoid Arthritis Treated with a Therapeutic Strategy Targeting Low Disease Activity, and Impact of Adverse Events on Physical Function
Abstract Number: 2870

Thresholds for Disease Activity Measures DAS28, CDAI, and RAPID3 Do Not Align with Clinical Practice Patterns of Rheumatoid Arthritis (RA) Disease Management Decisions
Abstract Number: 2765

Thyroid Artery Involvement Detected By Colour-Doppler Ultrasonography in an Incipient, Single Centre Giant Cell Arteritis Cohort

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].